Literature DB >> 20112340

Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth.

Yaxiong Tang1, Xuesen Li, Zhongbo Liu, Anne R Simoneau, Jun Xie, Xiaolin Zi.   

Abstract

Limited success has been achieved in extending the survival of patients with metastatic and hormone-refractory prostate cancer (HRPC). There is a strong need for novel agents in the treatment and prevention of HRPC. We have shown that flavokawain B (FKB), a kava chalcone, is about 4- to 12-fold more effective in reducing the cell viabilities of androgen receptor (AR)-negative, HRPC cell lines DU145 and PC-3 than AR-positive, hormone-sensitive prostate cancer cell lines LAPC4 and LNCaP, with minimal effect on normal prostatic epithelial and stromal cells. FKB induces apoptosis with an associated increased expression of proapoptotic proteins: death receptor-5, Bim and Puma and a decreased expression of inhibitors of apoptosis protein: XIAP and survivin. Among them, Bim expression was significantly induced by FKB as early as 4 hr of the treatment. Knockdown of Bim expression by short-hairpin RNAs attenuates the inhibitory effect on anchorage-dependent and -independent growth and caspase cleavages induced by FKB. These findings suggest that the effect of FKB, at least in part, requires Bim expression. In addition, FKB synergizes with TRAIL for markedly enhanced induction of apoptosis. Furthermore, FKB treatment of mice bearing DU145 xenograft tumors results in tumor growth inhibition and increases Bim expression in tumor tissues. Together, these results suggest robust mechanisms for FKB induction of apoptosis preferentially for HRPC and the potential usefulness of FKB for prevention and treatment of HRPC in an adjuvant setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112340      PMCID: PMC2888737          DOI: 10.1002/ijc.25210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

Review 1.  Trends and patterns of prostate cancer: what do they suggest?

Authors:  A W Hsing; S S Devesa
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

Review 2.  Mechanisms leading to the development of hormone-resistant prostate cancer.

Authors:  Susan Kasper; Michael S Cookson
Journal:  Urol Clin North Am       Date:  2006-05       Impact factor: 2.241

3.  From castration-induced apoptosis of prostatic epithelium to the use of apoptotic genes in the treatment of prostate cancer.

Authors:  Ye Zhang; Bicheng Nan; Jiang Yu; Tithi Snabboon; Francesca Andriani; Marco Marcelli
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 4.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 5.  The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

Authors:  A Mosca; A Berruti; L Russo; M Torta; L Dogliotti
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

6.  Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells.

Authors:  S Gupta; F Afaq; H Mukhtar
Journal:  Biochem Biophys Res Commun       Date:  2001-10-05       Impact factor: 3.575

Review 7.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

8.  Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses.

Authors:  H Ranjith W Dharmaratne; N P Dhammika Nanayakkara; Ikhlas A Khan
Journal:  Phytochemistry       Date:  2002-02       Impact factor: 4.072

9.  The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Authors:  Ren Jie Jin; Yongsoo Lho; Linda Connelly; Yongqing Wang; Xiuping Yu; Leshana Saint Jean; Thomas C Case; Katharine Ellwood-Yen; Charles L Sawyers; Neil A Bhowmick; Timothy S Blackwell; Fiona E Yull; Robert J Matusik
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

10.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Authors:  Carolyn Waugh Kinkade; Mireia Castillo-Martin; Anna Puzio-Kuter; Jun Yan; Thomas H Foster; Hui Gao; Yvonne Sun; Xuesong Ouyang; William L Gerald; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more
  34 in total

Review 1.  NutriTRAILomics in prostate cancer: time to have two strings to one's bow.

Authors:  Ammad Ahmad Farooqi; Aamir Rana; Asma M Riaz; Ammara Khan; Muhammad Ali; Sara Javed; Shahzeray Mukhtar; Sehrish Minhaj; Javeria Rafique Rao; Javairia Rajpoot; Rafia Amber; Fiza Asif Javed; Reema Khanum; Shahzad Bhatti
Journal:  Mol Biol Rep       Date:  2011-12-06       Impact factor: 2.316

Review 2.  Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

Authors:  Simeng Wen; Yuanjie Niu; Soo Ok Lee; Chawnshang Chang
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

Review 3.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

4.  Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.

Authors:  Zhongbo Liu; Xia Xu; Xuesen Li; Shuman Liu; Anne R Simoneau; Feng He; Xue-Ru Wu; Xiaolin Zi
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-11

Review 5.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

6.  Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J mice.

Authors:  Pablo Leitzman; Sreekanth C Narayanapillai; Silvia Balbo; Bo Zhou; Pramod Upadhyaya; Ahmad Ali Shaik; M Gerard O'Sullivan; Stephen S Hecht; Junxuan Lu; Chengguo Xing
Journal:  Cancer Prev Res (Phila)       Date:  2014-01

7.  New withanolides with TRAIL-sensitizing effect from Physalis pubescens L.

Authors:  Li-Xia Chen; Gui-Yang Xia; Hao He; Jian Huang; Feng Qiu; Xiao-Lin Zi
Journal:  RSC Adv       Date:  2016-05-26       Impact factor: 3.361

8.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

9.  Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.

Authors:  Toshinori Sakai; Ramez N Eskander; Yi Guo; Kap Jung Kim; Jason Mefford; Justin Hopkins; Nitin N Bhatia; Xiaolin Zi; Bang H Hoang
Journal:  J Orthop Res       Date:  2011-12-29       Impact factor: 3.494

Review 10.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.